MLi-2 is an a potent, highly selective, orally available, brain penetrant inhibitor of LRRK2 with an IC50 of 0.76 nM.

MLN 3897 is a potent, specific and orally active antagonist of CCR1 with IC50 of 0.8 nM in competition binding assays, 500-fold selectivity over CCR5.

MLN0905 is a mall-molecule and potent inhibitor of PLK1 with IC50 of 2 nM.

MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM.

MLN3126 (MLN 3126, MLN-3126) is a potent, selective, orally available CCR9 antagonist with IC50 of 6.3 nM (CCL25-induced calcium mobilization).

MLN-4760 is a potent and selective human ACE2 inhibitor (IC50, 0.44 nM), with excellent selectivity (>5000-fold) versus related enzymes including human testicular ACE (IC50, >100 μM) and bovine carboxypeptidase A (CPDA; IC50, 27 μM).

MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM; exhibits more than 40-fold selective for Aurora A than Aurora B.

MLR-1023 is a chemical compound which inhibits acid secretion in animal models and also acts as a bronchodilator in histamine-challenged animals.

MLS 0038949 is a potent, selective tissue-nonspecific alkaline phosphatase (TNAP) inhibitor with IC50 of 0.19 uM, shows no activity against IAP and PLAP (IC50>100 uM).

MLS 0263839 is a potent, specific inhibitor of the phosphatase PHOSPHO1 with IC50 of 0.14 uM, shows minimal cross-inhibition of TNAP and no inhibition of ENPP1 activity.

MLS-0322825 is a novel potent low-molecular-weight protein tyrosine phosphatase (LMPTP) inhibitor with IC50 of 3.3 uM.

MLS-0437605 is a specific inhibitor of dual-specificity phosphatase 3 (DUSP3) with IC50 of 3.7 uM, 7-fold selectivity over USP22 and >4-fold selectivity over other 10 PTPs (HePTP, TCPTP, PTP1B, etc.).

MLS1082 is a novel positive allosteric modulator of the D1 dopamine receptor, potentiatse dopamine-stimulated G-protein- and β-arrestin-mediated signaling and increase the affinity of dopamine for the D1 receptor with low micromolar potencies..

MLS-1547 is a G protein-biased agonist of dopamine D2 receptors (EC50 = 0.37 μM in a calcium mobilization assay).

MLS6585 is a novel positive allosteric modulator of the D1 dopamine receptor, potentiatse dopamine-stimulated G-protein- and β-arrestin-mediated signaling and increase the affinity of dopamine for the D1 receptor with low micromolar potencies..

MM 07 is a biased apelin receptor agonist, with a KD of 300 nM in CHO-K1 cells and a KD of 172 nM in human heart.

MM41 is a quadruplex-interactive compound which binds strongly to the quadruplexes encoded in the promoter sequences of the BCL-2 and k-RAS genes.

MM-589 is a potent inhibitor of WD repeat domain 5 (WDR5) and mixed lineage leukemia (MLL) interaction. MM-589 binds to WDR5 with an IC50 of 0.90 nM and inhibits the MLL H3K4 methyltransferase activity with an IC50 of 12.7 nM.

MMBO is a potent, highly selective, brain penetrant, orally active inhibitor of GSK-3 with IC50 of 37 and 53 nM for GSK-3α and GSK-3β, respectively.

MMK7 inhibitor 4a is a potent, sepecific, covalent inhibitor of MMK7, displays >800-fold selectivity over EGFR-WT and EGFR-L858R/T790M.

MMP13-IN-24f is a potent, selective, and orally active MMP-13 inhibitor with IC50/Ki of 0.5/0.19 nM, shows no activity against MMP-1 or TACE (IC50>10 uM).

MMP13-IN-31f is a highly potent, selective, orally bioavailable MMP-13 inhibitor with IC50 of 0.036 nM.